BMS’s Opdivo May Be Next Casualty Of US FDA’s Perioperative Trial Redesign Push

 
• By Sarah Karlin-Smith
  
two sets of business people with giant speaking bubbles that are disconnected and broken showing visual of communication breakdown
The Imfinzi ODAC meeting revealed potentially broader communication problems between the FDA and industry. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards